FENC — Fennec Pharmaceuticals Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$9.89
Market Cap$346M
Float16.9M
Shares Outstanding34.7M
P/E (Forward)32.36
Price/Sales (TTM)6.78
vs. Analyst Target+53.4% to analyst PT
Profit Margin-16.42%
Operating Margin (TTM)-0.79%
Revenue (TTM)$51.0M
Dividend RateNone
Analyst Target Price$15.17 (5 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $170,000 -$18.1M $170,000 -$17.7M
2021 $170,000 -$17.2M N/A -$17.1M
2022 $1.5M -$22.8M $1.4M -$21.7M
2023 $21.3M -$16.0M $20.0M -$12.4M
2024 $47.5M -$436,000 $44.4M $4.8M
2025 $44.6M -$9.7M $40.9M -$7.5M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $9.7M -$3.2M
Sep 2025 $12.5M -$638,000
Dec 2025 $13.8M -$4.8M
Mar 2026 $15.1M $201,000

Ownership & Float

Insider Ownership14.4%
Institutional Ownership54.3%
Short Float6.3%
% of All Funds Holding1.02%
Number of Funds Holding84

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$7.48Near-term / short-term trend
Weekly40-Week SMA$8.00Medium-term trend
Weekly80-Week SMA$7.45Cyclical trend (business cycle)
Weekly200-Week SMA$7.79Secular trend (multi-year)
Monthly10-Month SMA$8.09Near-term monthly trend
Monthly20-Month SMA$7.40Medium-term monthly trend
Monthly40-Month SMA$7.77Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$6.50 support 1.88x 0 months ago
$6.10 support 1.09x 11 months ago
$4.50 support 1.30x 17 months ago
$11.00 resistance 1.35x 24 months ago

Historical Earnings Reactions (35 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.17% 0.00% 40.00% 13.78% -9.98%
1 Day -0.54% 0.00% 48.57% 7.14% -26.75%
1 Week -1.41% 1.52% 51.43% 25.91% -31.44%
2 Weeks 0.06% 0.52% 51.43% 28.28% -35.22%
1 Month -2.49% 0.99% 54.29% 31.80% -55.39%

Next earnings: May 12, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-0.8%55.6%9
Feb3.7%66.7%9
Mar-6.1%33.3%9
Apr-1.1%55.6%9
May1.6%37.5%8
Jun1.9%50.0%8
Jul2.6%62.5%8
Aug-3.4%50.0%8
Sep3.8%62.5%8
Oct-1.8%33.3%9
Nov4.1%66.7%9
Dec2.8%55.6%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.03% 44.5% 409
Tuesday 0.18% 51.8% 450
Wednesday -0.22% 45.5% 446
Thursday 0.33% 49.5% 438
Friday 0.02% 46.2% 439

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 54.3%

Insider Transactions — Smart Summary

Total insider ownership: 14.4%

12-Month Insider Activity Summary

Total Filings19
Net Value+N/A
Net Shares Change-1,344,047
% of Float-8.0%
C-Suite Filings0
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Southpoint Capital Advisors LP -$10.3M 4 4 sell
Raykov Rosty -$190,687.08 5 N/A
RALLIS CHRIS A -$23,756.48 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-10-06 – 2025-10-14 3 3 -$745,432.037

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-12-29 Southpoint Capital Advisors LP -$7.5M Transaction at $7.50, now +31.9%
2026-05-12 RALLIS CHRIS A -$23,756.48 Transaction at $4.74, now +108.6%
2025-11-17 Southpoint Capital Advisors LP -$2.0M Transaction at $8.27, now +19.5%
2026-03-03 Raykov Rosty -$46,045.34 Transaction at $5.40, now +83.0%
2025-11-20 Southpoint Capital Advisors LP -$170,048.006 Transaction at $8.79, now +12.5%
2025-10-09 Southpoint Capital Advisors LP -$636,227.297 Transaction at $9.48, now +4.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Fennec Pharmaceuticals Inc (FENC) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for FENC on Trend Edge →